trending Market Intelligence /marketintelligence/en/news-insights/trending/Q3SOt7ZMin8hYTK1vbwoFA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Boston Scientific's earnings rise YOY for Q4'16

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Boston Scientific's earnings rise YOY for Q4'16

Boston Scientific Corp. reported fourth-quarter 2016 after-tax net income of $124 million, or 9 cents per share, compared with a loss of $142 million, or 11 cents per share, in the year-ago period.

After-tax adjusted net income was $415 million, or 30 cents per share, versus $362 million, or 26 cents per share, in the same period a year ago.

The S&P Capital IQ consensus normalized EPS estimate for the fourth quarter was 29 cents.

Boston Scientific generated sales of $2.19 billion during the fourth quarter, up 11% from $1.98 billion in the prior-year period.

After-tax net income for 2016 was $347 million, or 25 cents per share, compared with a loss of $239 million, or 18 cents per share, in 2015. After-tax adjusted net income was $1.53 billion, or $1.11 per share, versus $1.27 billion, or 93 cents per share, a year ago.

The S&P Capital IQ normalized EPS consensus estimate for 2016 was $1.10.

Boston Scientific expects sales for the first quarter of 2017 in a range of $2.05 billion to $2.10 billion. GAAP EPS for the quarter is expected to be between 18 cents and 21 cents, with adjusted EPS in the range of 29 cents to 31 cents. The S&P Capital IQ consensus normalized EPS estimate for the quarter is 30 cents.

The company estimates revenue for the full year 2017 to be in a range of $8.68 billion to $8.88 billion. GAAP EPS for the year is expected to be between 86 cents and 91 cents, with adjusted EPS in the range of $1.22 to $1.26. The S&P Capital IQ consensus normalized EPS estimate for 2017 is $1.24.